These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11060671)

  • 1. Interference with complement regulatory molecules as a possible therapeutic strategy in HIV infection.
    Pintér C; Beltrami S; Stoiber H; Negri DR; Titti F; Clivio A
    Expert Opin Investig Drugs; 2000 Feb; 9(2):199-205. PubMed ID: 11060671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human complement proteins C3b, C4b, factor H and properdin react with specific sites in gp120 and gp41, the envelope proteins of HIV-1.
    Stoiber H; Schneider R; Janatova J; Dierich MP
    Immunobiology; 1995 Jun; 193(1):98-113. PubMed ID: 7590866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of several complement proteins with gp120 and gp41, the two envelope glycoproteins of HIV-1.
    Stoiber H; Ebenbichler C; Schneider R; Janatova J; Dierich MP
    AIDS; 1995 Jan; 9(1):19-26. PubMed ID: 7893437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking HIV entry.
    Buzko OV; Shokat KM
    Nat Struct Biol; 1999 Oct; 6(10):906-8. PubMed ID: 10504719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 9th National Retrovirus Conference: new treatments, new choices.
    Laurence J
    AIDS Patient Care STDS; 2002 May; 16(5):193-5. PubMed ID: 12055025
    [No Abstract]   [Full Text] [Related]  

  • 6. HIV entry inhibitors: progress in development and application.
    Lai WH; Huang L; Chen CH
    Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV fusion and its inhibition.
    LaBranche CC; Galasso G; Moore JP; Bolognesi DP; Hirsch MS; Hammer SM
    Antiviral Res; 2001 May; 50(2):95-115. PubMed ID: 11369431
    [No Abstract]   [Full Text] [Related]  

  • 8. New advances in HIV entry inhibitors development.
    Rusconi S; Scozzafava A; Mastrolorenzo A; Supuran CT
    Curr Drug Targets Infect Disord; 2004 Dec; 4(4):339-55. PubMed ID: 15578975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV/AIDS. Report of novel treatment aimed at latent HIV raises the 'c word'.
    Cohen J
    Science; 2005 Aug; 309(5737):999-1000. PubMed ID: 16099956
    [No Abstract]   [Full Text] [Related]  

  • 10. [T-20: a fusion inhibitor].
    Iafolla M
    Sidahora; 2002; (3):20-2. PubMed ID: 12703471
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of complement in HIV infection.
    Stoiber H; Clivio A; Dierich MP
    Annu Rev Immunol; 1997; 15():649-74. PubMed ID: 9143703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro.
    Robinson WE; Kawamura T; Lake D; Masuho Y; Mitchell WM; Hersh EM
    J Virol; 1990 Nov; 64(11):5301-5. PubMed ID: 1698995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins.
    Steffen I; Pöhlmann S
    Curr Pharm Des; 2010; 16(9):1143-58. PubMed ID: 20030613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement activation by human monoclonal antibodies to human immunodeficiency virus.
    Spear GT; Takefman DM; Sullivan BL; Landay AL; Zolla-Pazner S
    J Virol; 1993 Jan; 67(1):53-9. PubMed ID: 7677959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retroviruses and opportunistic infections - 13th annual meeting.
    Martinez E
    IDrugs; 2006 Apr; 9(4):250-2. PubMed ID: 16596475
    [No Abstract]   [Full Text] [Related]  

  • 16. Current evidence and future directions for targeting HIV entry: therapeutic and prophylactic strategies.
    D'Souza MP; Cairns JS; Plaeger SF
    JAMA; 2000 Jul; 284(2):215-22. PubMed ID: 10889596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
    Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The treatment pipeline: new therapies are on the way.
    Boyle BA
    AIDS Read; 1999 Nov; 9(8):519-20, 523-5, 528-9. PubMed ID: 11082727
    [No Abstract]   [Full Text] [Related]  

  • 19. Researchers explore new anti-HIV agents.
    Stephenson J
    JAMA; 2002 Apr; 287(13):1635-7. PubMed ID: 11926873
    [No Abstract]   [Full Text] [Related]  

  • 20. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
    Pan C; Liu S; Jiang S
    J Formos Med Assoc; 2010 Feb; 109(2):94-105. PubMed ID: 20206833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.